ALLEI Stock Analysis: Alleima (publ) | ST
Steel | ST, Sweden | Market Cap: 28.143m SEK | 12M Return: 62.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.8M
EPS Trend: -92.2%
Qual. Beats: 1
Rev. Trend: -92.8%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 3.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alleima AB (publ) is a Swedish materials company that manufactures and sells stainless steels, special alloys, medical wires and components, and electric heating systems. It operates through three divisions-Tube, Kanthal, and Strip-and sells across Europe, North America, Asia, and other international markets. End markets span oil and gas, chemical and petrochemical, industrial heating, medical, transportation, mining and construction, nuclear, and hydrogen and renewable energy. The company was founded in 1862 and is headquartered in Sandviken, Sweden.
Its product range covers tubes for oil and gas extraction, heat exchangers, hydraulic and instrumentation tubing, metallic and ceramic heating elements, ultra-fine wire and components for medical devices such as pacemakers, neurostimulation, and glucose monitors, as well as tubes and coated strip steel for hydrogen, carbon capture, offshore wind, and electrolyzer applications. As a GICS-classified Steel producer, Alleima operates in a capital-intensive, cyclical industry where earnings are sensitive to industrial production, energy, and infrastructure activity, and where product mix toward specialty alloys, medical, and energy-transition applications is a key differentiator versus commodity-grade peers.
- Tube division order book tied to oil and gas capex
- Medical wire revenue grows on pacemaker and diabetes device demand
- Hydrogen and nuclear energy transition lifts special alloy orders
| Net Income: 913.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.25 > 1.0 |
| NWC/Revenue: 44.22% < 20% (prev 41.14%; Δ 3.08% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.83b > Net Income 913.0m |
| Net Debt (168.0m) to EBITDA (2.34b): 0.07 < 3 |
| Current Ratio: 2.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (250.7m) vs 12m ago -0.07% < -2% |
| Gross Margin: 20.50% > 18% (prev 20.14%; Δ 0.36% > 0.5%) |
| Asset Turnover: 78.26% > 50% (prev 84.53%; Δ -6.27% > 0%) |
| Interest Coverage Ratio: 10.22 > 6 (EBIT TTM 1.32b / Interest Expense TTM 129.0m) |
| A: 0.34 (Total Current Assets 12.8b - Total Current Liabilities 4.76b) / Total Assets 23.4b |
| B: 0.70 (Retained Earnings 16.3b / Total Assets 23.4b) |
| C: 0.06 (EBIT TTM 1.32b / Avg Total Assets 23.2b) |
| D: 2.59 (Book Value of Equity 16.9b / Total Liabilities 6.51b) |
| Altman-Z'' = 7.63 = AAA |
| DSRI: 1.11 (Receivables 4.07b/3.94b, Revenue 18.2b/19.5b) |
| GMI: 0.98 (GM 20.14% / 20.50%) |
| AQI: 0.96 (AQ_t 0.10 / AQ_t-1 0.10) |
| SGI: 0.93 (Revenue 18.2b / 19.5b) |
| TATA: -0.04 (NI 913.0m - CFO 1.83b) / TA 23.4b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of July 29, 2026, the stock is trading at SEK 112.40 with a total of 221,915 shares traded. Over the past week, the price has changed by +5.05%, over one month by +26.29%, over three months by +42.48% and over the past year by +62.11%.
Current recommended Stop Loss: 108.30 (which is 3.6% or 1.3 ATR below the current price).
Alleima (publ) has no consensus analysts rating.
P/E Trailing = 30.9066
P/E Forward = 18.315
P/S = 1.5473
P/B = 1.6111
Revenue TTM = 18.2b SEK
EBIT TTM = 1.32b SEK
EBITDA TTM = 2.34b SEK
Long Term Debt = 928.0m SEK (from longTermDebt, last quarter)
Short Term Debt = 142.0m SEK (from shortTermDebt, last quarter)
Debt = 1.49b SEK (from shortLongTermDebtTotal, last quarter) + Leases 417.0m
Net Debt = 168.0m SEK (calculated: Debt 1.49b - CCE 1.32b)
Enterprise Value = 28.3b SEK (28.1b + Debt 1.49b - CCE 1.32b)
Interest Coverage Ratio = 10.22 (Ebit TTM 1.32b / Interest Expense TTM 129.0m)
EV/FCF = 36.67x (Enterprise Value 28.3b / FCF TTM 772.0m)
FCF Yield = 2.73% (FCF TTM 772.0m / Enterprise Value 28.3b)
FCF Margin = 4.24% (FCF TTM 772.0m / Revenue TTM 18.2b)
Net Margin = 5.02% (Net Income TTM 913.0m / Revenue TTM 18.2b)
Gross Margin = 20.50% ((Revenue TTM 18.2b - Cost of Revenue TTM 14.5b) / Revenue TTM)
Gross Margin QoQ = 27.02% (prev 21.77%)
Tobins Q-Ratio = 1.21 (Enterprise Value 28.3b / Total Assets 23.4b)
Interest Expense / Debt = 8.68% (Interest Expense 129.0m / Debt 1.49b)
Taxrate = 25.83% (318.0m / 1.23b)
NOPAT = 978.3m (EBIT 1.32b * (1 - 25.83%))
Current Ratio = 2.69 (Total Current Assets 12.8b / Total Current Liabilities 4.76b)
Debt / Equity = 0.09 (Debt 1.49b / totalStockholderEquity, last quarter 16.9b)
Debt / EBITDA = 0.07 (Net Debt 168.0m / EBITDA 2.34b)
Debt / FCF = 0.22 (Net Debt 168.0m / FCF TTM 772.0m)
Total Stockholder Equity = 16.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.93% (Net Income 913.0m / Total Assets 23.4b)
RoE = 5.46% (Net Income TTM 913.0m / Total Stockholder Equity 16.7b)
RoCE = 7.48% (EBIT 1.32b / Capital Employed (Equity 16.7b + L.T.Debt 928.0m))
RoIC = 5.47% (NOPAT 978.3m / Invested Capital 17.9b)
WACC = 8.73% (E(28.1b)/V(29.6b) * Re(8.85%) + D(1.49b)/V(29.6b) * Rd(8.68%) * (1-Tc(0.26)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 2.60 | Cagr: -0.03%
[DCF] Terminal Value 75.35% ; FCFF base≈744.8m ; Y1≈807.6m ; Y5≈997.6m
[DCF] Fair Price = 56.64 (EV 14.3b - Net Debt 168.0m = Equity 14.2b / Shares 250.2m; r=8.73% [WACC]; 5y FCF grow 9.66% → 2.50% )
EPS Correlation: -92.23 | EPS CAGR: -20.25% | SUE: 0.92 | # QB: 1
Revenue Correlation: -92.79 | Revenue CAGR: -4.55% | SUE: 1.27 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.81 | Chg30d=-1.01% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=4.87 | Chg30d=+5.10% | Revisions=+0% | GrowthEPS=+5.3% | GrowthRev=+0.2%
EPS next Year (2027-12-31): EPS=5.95 | Chg30d=+6.29% | Revisions=+0% | GrowthEPS=+22.3% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: -12% (up=2, down=3)